Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study
Seth E. Karol(St. Jude Children's Research Hospital), Jeffrey E. Rubnitz(St. Jude Children's Research Hospital), Jeffery M. Klco(St. Jude Children's Research Hospital), Norman J. Lacayo(Lucile Packard Children's Hospital), Amit Budhraja(St. Jude Children's Research Hospital), Kristin Canavera(St. Jude Children's Research Hospital), Tammy L. Palenski(AbbVie (United States)), Joseph T. Opferman(St. Jude Children's Research Hospital), Ahmed Hamed Salem(Ain Shams University), Stanley Pounds(St. Jude Children's Research Hospital), Thomas Alexander(University of North Carolina at Chapel Hill), Su Y. Kim(AbbVie (United States)), Soumyasri Das Gupta(St. Jude Children's Research Hospital), Joshua Wolf(St. Jude Children's Research Hospital), Paul E. Mead(St. Jude Children's Research Hospital), Lei Wang(St. Jude Children's Research Hospital), Ching‐Hon Pui(St. Jude Children's Research Hospital)
Cited by 167
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Treatment of Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2006|2k